. 2000 Jan;74(2):661–668. doi: 10.1128/jvi.74.2.661-668.2000

TABLE 1.

Clinical, histological, and virological features of the 26 patients studied and characteristics of the HVR-1 quasispecies before treatment

Patient^a	Sex	Age (yr)	Knodell score	Genotype^b	HCV RNA concn (log copies/ml)^c	Normalized entropy		Mean genetic distance (SEM)^d	Mutational changes^e
Patient^a	Sex	Age (yr)	Knodell score	Genotype^b	HCV RNA concn (log copies/ml)^c	Nucleotide	Amino acid	Mean genetic distance (SEM)^d	Mean K_s (SEM)	Mean K_a (SEM)	K_a/K_s
R1	Female	34	7	1b	5.79	0.525	0.525	0.2250 (0.0100)	0.1200 (0.0076)	0.2890 (0.0196)	2.41
R2	Male	25	10	3a	3.95	0.132	0.066	0.0035 (0.0003)	0.0050 (0.0011)	0.0030 (0.0005)	0.60
R3	Female	29	6	3a	4.91	0.328	0.291	0.0247 (0.0020)	0.0050 (0.0010)	0.0330 (0.0029)	6.60
R4	Female	33	10	3a	5.86	0.494	0.385	0.1280 (0.0070)	0.2260 (0.0244)	0.1240 (0.0127)	0.55
R5	Male	32	9	3a	5.58	0.322	0.322	0.0630 (0.0050)	0.0320 (0.0043)	0.0780 (0.0089)	2.44
R6	Male	37	10	3a	4.63	0.507	0.275	0.0135 (0.0010)	0.0225 (0.0020)	0.0110 (0.0012)	0.50
R7	Male	32	4	3a	5.97	0.647	0.586	0.0544 (0.0050)	0.0180 (0.0031)	0.0670 (0.0091)	3.72
R8	Female	34	4	3a	4.94	0.196	0.063	0.0023 (0.0002)	0.0000 (0.0000)	0.0004 (0.0005)	1.04
R9	Female	33	3	3a	4.98	0.786	0.549	0.1360 (0.0050)	0.0581 (0.0034)	0.1820 (0.0096)	3.13
R10	Female	30	8	2	5.67	0.618	0.483	0.1390 (0.0070)	0.1250 (0.0090)	0.1440 (0.0114)	1.15
R11	Female	39	10	2	4.19	0.461	0.461	0.0135 (0.0010)	0.0040 (0.0008)	0.0180 (0.0009)	4.50
R12	Male	24	4	2	4.19	0.496	0.496	0.1020 (0.0070)	0.0450 (0.0047)	0.1370 (0.0135)	3.04
R13	Male	57	12	2	4.11	0.365	0.328	0.0110 (0.0010)	0.0090 (0.0014)	0.0120 (0.0007)	1.33
Mean (group)		34	7		4.98	0.452	0.372	0.0705 (0.0040)	0.0515 (0.0048)	0.0845 (0.0070)	2.39
NR1	Female	55	10	1b	6.08	0.837	0.712	0.1850 (0.0080)	0.1080 (0.0063)	0.2220 (0.0136)	2.06
NR2	Male	28	4	3a	4.80	0.899	0.876	0.1400 (0.0040)	0.2490 (0.0110)	0.1200 (0.0042)	0.48
NR3	Female	41	13	3a	4.65	0.440	0.440	0.0300 (0.0010)	0.0300 (0.0021)	0.0330 (0.0015)	1.10
NR4	Female	28	6	3a	5.91	0.812	0.789	0.0675 (0.0020)	0.0510 (0.0049)	0.0635 (0.0027)	1.24
NR5	Male	31	8	3a	5.13	0.236	0.132	0.0063 (0.0004)	0.0190 (0.0019)	0.0030 (0.0048)	0.16
NR6	Male	57	8	3a	4.99	0.514	0.296	0.0525 (0.0020)	0.0540 (0.0040)	0.0560 (0.0040)	1.04
NR7	Male	41	7	3a	5.48	0.593	0.204	0.0180 (0.0010)	0.0000 (0.0000)	0.0250 (0.0015)	3.50
NR8	Female	32	6	3a	6.14	0.769	0.769	0.1260 (0.0050)	0.1960 (0.0099)	0.1040 (0.0062)	0.53
NR9	Female	35	8	3a	6.01	0.708	0.631	0.1460 (0.0070)	0.2019 (0.0156)	0.2018 (0.0138)	1.00
NR10	Female	53	6	2	6.08	0.858	0.786	0.1150 (0.0040)	0.1180 (0.0070)	0.1230 (0.0061)	1.04
NR11	Female	59	11	2	3.95	0.167	0.167	0.0250 (0.0040)	0.0000 (0.0000)	0.0400 (0.0090)	5.00
NR12	Male	43	6	2	4.07	0.569	0.479	0.0550 (0.0040)	0.0650 (0.0082)	0.0690 (0.0069)	1.06
NR13	Male	54	8	2	3.60	0.288	0.193	0.0240 (0.0020)	0.0140 (0.0021)	0.0280 (0.0041)	1.65
Mean (group)		43	8		5.15	0.591	0.498	0.0762 (0.0034)	0.0844 (0.0060)	0.0848 (0.0066)	1.53

R, responders, characterized by viral eradication 6 months after IFN-α therapy was stopped; NR, nonresponders, characterized by insufficient effect of IFN-α to obtain viral eradication.

Genotype was determined by the Inno-Lipa II HCV method.

HCV RNA was measured by the Amplicor Monitor assay.

The genetic distances within samples were calculated by using the DNADIST program in the PHYLIP package version 3.752.

The proportions of synonymous substitutions per synonymous site (K_s) and of nonsynonymous substitutions per nonsynonymous site (K_a) were calculated by means of the MEGA program.